A Phase 3 interventional study of Mindfulness-Based Cognitive Therapy in Multiple Sclerosis, sponsored by Robert Simpson. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Robert Simpson · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will use a waiting list randomized controlled trial design with a mixed-methods research approach, including both quantitative and qualitative methods. Randomization helps minimize research bias and controls for participant and contextual factors that might otherwise make interpretation of results challenging. We will recruit 152 people with multiple sclerosis (PwMS) with any type of MS, who also have mild-moderate depression, aged 18 or greater, and able to understand spoken and written English.
For the quantitative part, we will examine how much change in depression there is following mindfulness-based cognitive therapy (MBCT), as well as whether participants attend the course and complete study measures or not, and how much participants complete MBCT home practices. We will also examine how much change there is in fatigue, sleep pain, quality of life, and anxiety.
For the qualitative part of the study, we will use semi-structured interviews to explore participant experiences of online MBCT, how people used online MBCT, what worked, what didn't and why, how online MBCT impacted self-management of depression, and suggestions for improving the course to make it more relevant for PwMS with depression.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
This study's planned enrollment of 152 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Robert Simpson is the lead sponsor of 5 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria will include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks
Other: Mindfulness-Based Cognitive Therapy
Waitlist control arm - participants receive no intervention initially but receive MBCT following data collection
Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks
Depression
Change in depression scores using the Hospital Anxiety and Depression Scale
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Self-efficacy
Self-efficacy, as measured by the Generalized Self-Efficacy Scale
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Self-management
Self-management, as measured by the Multiple-Sclerosis Self-Management Scale-Revised
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Stigma
Stigma, as measured by the Stigma Scale for Chronic Illness-8
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Fatigue
Fatigue as measured by the Modified Fatigue Impact Scale
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Sleep
Sleep as measured by the Insomnia Severity Index
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Change in pain
Pain as measured by the Pain Effects Scale
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Change in quality of life
Quality of life as measured by the Multiple Sclerosis Impact Scale-29
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Anxiety
Anxiety as measured by Hospital Anxiety and Depression Scale -Anxiety
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Mindfulness
Mindfulness as measured by The Five-facet Mindfulness Questionnaire
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Self-compassion
Self-compassion, measured using the The Self-Compassion Scale-short form
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Emotion regulation
Emotion regulation, as measured by The Difficulties with Emotional Regulation Scale short-form
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Group attendance
Group attendance in those allocated to tailored online MBCT
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Group climate
Group climate using the Climate Questionnaire-Engage Scale
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Therapeutic alliance
Therapeutic alliance as measured by the Working Alliance Inventory
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Depressive symptoms
Depressive symptoms as measured by the Beck Depression Inventory II (BDI-II)
Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)
Implementation
Implementation, as informed by the Proctor's taxonomy
Time frame: Throughout the study and up to 12 months post-intervention
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Nov 2028, 27 months later.
Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Robert Simpson